Micafungin Agmed (Micafungin)

Micafungin Agmed is an echinocandin antifungal that targets Candida species in serious infections.

• Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections in adults and children.
• Esophageal candidiasis: resolves mucosal infection of the esophagus caused by Candida.
• Candida peritonitis and intra‑abdominal infections: used to manage intra‑abdominal Candida contamination.
• Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive candidiasis in transplant recipients.

• Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for synthesising β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. By disrupting cell‑wall formation, the drug leads to osmotic instability and fungal cell lysis, while having minimal effect on human cells that lack this pathway.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Fever: transient elevation of body temperature during infusion.
• Nausea: mild gastrointestinal discomfort.
• Vomiting: occasional emesis following administration.
• Headache: mild to moderate headache reported.
• Rash: skin erythema or pruritus.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring monitoring.
• Anaphylaxis: acute, life‑threatening hypersensitivity reaction.
• Severe infusion‑related reactions: hypotension, bronchospasm, or chest discomfort.
• Renal impairment: acute kidney injury in susceptible patients.
• Neutropenia: marked reduction in neutrophil count.
• Stevens‑Johnson syndrome: rare severe cutaneous adverse reaction.

When using Micafungin Agmed, clinicians should observe several safety measures.

• Renal function: monitor serum creatinine and urine output regularly.
• Liver function: assess transaminases and bilirubin before and during therapy.
• Hypersensitivity: discontinue immediately if severe allergic reaction occurs.
• Drug interactions: review concomitant medications for potential pharmacokinetic effects.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin may interact with several agents, requiring attention to dosage and monitoring.

Major Interactions (Avoid)

• Cyclosporine: may increase micafungin exposure, raising toxicity risk.
• Rifampin: can markedly reduce micafungin plasma levels, compromising efficacy.
• Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin): may lower micafungin concentrations.

Moderate Interactions (Monitor Closely)

• Azole antifungals (fluconazole, voriconazole): may increase micafungin levels, necessitating liver function monitoring.
• Warfarin: potential alteration of INR, requiring more frequent coagulation checks.